Page last updated: 2024-10-22

alprenolol and Asthma

alprenolol has been researched along with Asthma in 10 studies

Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"We used mice with no detectable systemic adrenaline (PNMT(-/-) ) and wild-type (WT) mice to study the effects of four β-blockers, alprenolol, carvedilol, propranolol and nadolol, in an ovalbumin sensitization and challenge (Ova S/C) murine model of asthma."3.81β-Blockers have differential effects on the murine asthma phenotype. ( Bond, RA; Bouvier, M; Forkuo, GS; Joshi, R; Knoll, BJ; Leff, P; Parra, S; Thanawala, VJ; Valdez, DJ, 2015)
" Chronic administration of alprenolol, a beta-blocker without inverse agonist properties, did not attenuate the asthma phenotype, suggesting that it is signaling by empty receptors, rather than agonist-induced beta(2)-AR signaling, that supports the asthma phenotype."1.35Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. ( Bond, RA; Dickey, BF; Hanania, NA; Knoll, BJ; Lin, R; Nguyen, LP; Omoluabi, O; Parra, S; Tuvim, MJ, 2009)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19908 (80.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thanawala, VJ1
Valdez, DJ1
Joshi, R1
Forkuo, GS1
Parra, S2
Knoll, BJ2
Bouvier, M1
Leff, P1
Bond, RA2
Nguyen, LP1
Lin, R1
Omoluabi, O1
Hanania, NA1
Tuvim, MJ1
Dickey, BF1
Stiles, GL1
Caron, MG1
Lefkowitz, RJ1
Galant, SP1
Duriseti, L1
Underwood, S1
Insel, PA1
Brooks, SM2
McGowan, K2
Altenau, P2
Bernstein, IL1
Peagler, J1
Ablad, B1
Carlsson, E1
Ek, L1
Gross, F1
Beumer, HM1
Simpson, FO1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma[NCT00670267]Phase 1/Phase 210 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Airway Hyper-reactivity Compared to Baseline (Change in PC20 Doubling Dose by Methacholine Challenge)

Bronchoprovocation assessment was done by doubling doses of methacholine in accordance with the methodology recommended by the American Thoracic Society in the official policy statement adopted by the ATS Board of Directors, July 1999 (Guidelines for Methacholine and Exercise Challenge Testing-1999). (NCT00670267)
Timeframe: Baseline to end of study (105 days)

Interventionmg/mL (Mean)
Open Label Treatment With Oral Nadolol1.8

Change in Asthma Control Questionnaire (ACQ) Score Compared to Baseline

In the E.F. Juniper Asthma Control Questionnaire, a lower number reflects better control of asthma symptoms. A positive change in ACQ score reflects a reduction in control compared to baseline; conversely, a negative change in ACQ score reflects an increase in control compared to baseline. The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). Clinic staff score the FEV1% predicted on a 7-point scale. The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). (NCT00670267)
Timeframe: Baseline to end of study (105 days)

Interventionunits on a scale (Mean)
Open Label Treatment With Oral Nadolol0.3

Mean Daily Dose at Study Termination Across Participants

The outcome measure describes the mean daily dose achieved by the subjects at study termination. This data includes one subject who terminated early, having reached 2.5mgs and subsequently reducing to 1.25mgs prior to dropping out. (NCT00670267)
Timeframe: Baseline to end of study (105 days)

Interventionmg (Mean)
Open Label Treatment With Oral Nadolol29.6

Percent Change in FEV1% Predicted From Baseline to End of Study

(NCT00670267)
Timeframe: Baseline to end of study (105 days)

Interventionpercent change in FEV1% predicted (Mean)
Open Label Treatment With Oral Nadolol-5.9

Daily Dose at Study Termination Across Participants

The outcome measure describes the final daily dose achieved by the subjects in this study. The subjects described below who finished on less than the highest dose (i.e., 1.25, 5, and 10mgs) had all been down-titrated one dose (i.e., from 2.5, 10, and 20mgs) prior to completing the study on the dose reported. (NCT00670267)
Timeframe: Baseline to end of study (105 days)

Interventionparticipants (Number)
1.25mgs2.5mgs5.0mgs10.0mgs20mgs40mgs
Open Label Treatment With Oral Nadolol101107

Reviews

3 reviews available for alprenolol and Asthma

ArticleYear
Beta-adrenergic receptors: biochemical mechanisms of physiological regulation.
    Physiological reviews, 1984, Volume: 64, Issue:2

    Topics: Adenylyl Cyclases; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; A

1984
Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function.
    Drugs, 1974, Volume: 7, Issue:1

    Topics: Adrenergic beta-Antagonists; Alprenolol; Asthma; Bronchi; Bronchial Spasm; Humans; Isoproterenol; Mu

1974
Beta-adrenergic receptor blocking drugs in hypertension.
    Drugs, 1974, Volume: 7, Issue:1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alprenolol; Antidepressive Agents; Antihy

1974

Other Studies

7 other studies available for alprenolol and Asthma

ArticleYear
β-Blockers have differential effects on the murine asthma phenotype.
    British journal of pharmacology, 2015, Volume: 172, Issue:20

    Topics: Adrenergic beta-Antagonists; Allergens; Alprenolol; Animals; Asthma; Bronchoalveolar Lavage Fluid; C

2015
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Feb-17, Volume: 106, Issue:7

    Topics: Alprenolol; Animals; Asthma; Bronchoconstrictor Agents; Disease Models, Animal; Epithelial Cells; Hu

2009
Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy.
    The New England journal of medicine, 1978, Oct-26, Volume: 299, Issue:17

    Topics: Adrenergic beta-Agonists; Alprenolol; Asthma; Humans; In Vitro Techniques; Neutrophils; Receptors, A

1978
Relationship between beta-adrenergic binding in lymphocyte and severity of disease in asthma.
    Chest, 1979, Volume: 75, Issue:2 Suppl

    Topics: Adult; Alprenolol; Asthma; Cell Membrane; Cells, Cultured; Culture Media; Female; Humans; Hydrocorti

1979
Relationship between numbers of beta adrenergic receptors in lymphocytes and disease severity in asthma.
    The Journal of allergy and clinical immunology, 1979, Volume: 63, Issue:6

    Topics: Adult; Alprenolol; Asthma; Binding Sites; Female; Forced Expiratory Volume; Humans; Lymphocytes; Mal

1979
Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists.
    Life sciences. Pt. 1: Physiology and pharmacology, 1973, Feb-01, Volume: 12, Issue:3

    Topics: Acetanilides; Adrenergic beta-Antagonists; Alprenolol; Amino Alcohols; Animals; Asthma; Blood Pressu

1973
[Current drugs. Therapy using -blockaders ( -adrenolytics)].
    Der Internist, 1973, Volume: 14, Issue:3

    Topics: Acetanilides; Adrenergic beta-Antagonists; Alprenolol; Amino Alcohols; Angina Pectoris; Arrhythmias,

1973